Tina S. Nova, Ph.D., serves as Veracyte’s general manager, Thyroid & Urology, leading the company’s flagship Afirma franchise in thyroid cancer and market-leading Decipher business in urologic cancers. Dr. Nova is a life science industry veteran with extensive experience building and leading novel genomics-based businesses. She most recently served as president and chief executive officer of Decipher Biosciences prior to Veracyte acquiring the company in March 2021. Prior to that, she was president and chief executive officer of Molecular Stethoscope, Inc., a molecular diagnostics company, and before that served as senior vice president and general manager of Illumina’s oncology business unit. From 2000 to 2014, Dr. Nova was a co-founder and director, president and chief executive officer of Genoptix Medical Laboratory, which was purchased by Novartis Pharmaceuticals Corporation. She has also held senior positions with Nanogen, Inc., Ligand Pharmaceuticals, Inc. and Hybritech, Inc. Dr. Nova currently serves on the board of directors for Arena Pharmaceuticals and Exagen. She holds a B.S. degree in Biological Sciences from the University of California, Irvine, and a Ph.D. in Biochemistry from the University of California, Riverside.
Tina S. Nova, Ph.D.
General Manager, Thyroid & Urologic Cancers